About Changchun Bcht Biotechnology Company

The company is an innovative biomedical enterprise mainly dedicated to infectious disease prevention and control. Since its establishment in 2004, it has mainly been engaged in R&D, production and sales of human vaccine products. Through years of development, it has gradually established a complete operating system around core products, and implemented quality management throughout the life cycle of products, including raw material procurement, project research and development, production management, product circulation, quality control and quality assurance. All aspects have strict management measures and internal control systems. The company is a high-tech biopharmaceutical enterprise specializing in R&D, production and sales of human vaccines. The company currently has approved vaccine products such as chickenpox vaccine, nasal spray influenza vaccine, and shingles vaccine. The company is a “high-tech enterprise” recognized by the Jilin Provincial Science and Technology Department and other departments. It is “Jilin Modern Vaccine Engineering Research Center”, “Jilin Vaccine Science and Technology Innovation Center”, “Changchun National Biological Industry Base Vaccine Engineering Research Center”, “Jilin Science and Technology Little Giant Enterprise”, “Jilin Provincial AAA 'Contract-abiding and Creditworthy Enterprises'”, “Jilin Provincial Quality and Integrity Enterprise”, “Changchun City's Top 100 Small and Medium Enterprises”, “Changchun Intellectual Property Demonstration Enterprise”, “Changchun City Top 100 Small and Medium Enterprises”, “Changchun City Intellectual Property Demonstration Enterprise” “Private enterprise” won the “3.15 China Pharmaceutical Company” in 2018 “Top Ten Influential Brands”.